Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4621 (RGT100) in advanced solid tumors
NCT03065023Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 3
01
Overview
Phase 2, open-label trial of MK-4621 in solid tumor (advanced stage) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced a Treatment-related Adverse Event, Number of Participants Who Experienced a Serious Adverse Event and 2 more. Started Apr 2017; status: terminated.
02
Drugs
MK-4621
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03065023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065023.